Organization, year | Document type | Country | Appraisal of Guidelines for Research & Evaluation II domain scores, %* | |||||
---|---|---|---|---|---|---|---|---|
Scope and purpose | Stakeholder involvement | Rigor of development | Clarity of presentation | Applicability | Editorial independence | |||
Canadian Cancer Society, 2017 (24) | Position statement | Canada | NA | NA | NA | NA | NA | NA |
Canadian Cancer Society, 2017 (25) | Position statement | Canada | NA | NA | NA | NA | NA | NA |
Centre of Excellence for Transgender Health, 2016 (26) | Guideline | United States | 81 | 56 | 29 | 81 | 27 | 0 |
International Planned Parenthood Federation, 2015 (27) | Position statement | United Kingdom | NA | NA | NA | NA | NA | NA |
Sherbourne Health Centre, 2015 (28) | Guideline | Canada | 64 | 44 | 16 | 25 | 6 | 0 |
Transgender Health Information Program, 2015 (5) | Guideline | Canada | 67 | 67 | 6 | 14 | 13 | 0 |
Centers for Disease Control and Prevention, 2013 (29) | Position statement | United States | NA | NA | NA | NA | NA | NA |
National Health Service, 2013 (30) | Guideline | United Kingdom | 64 | 25 | 0 | 28 | 17 | 0 |
American College of Obstetricians and Gynecologists, 2011 (31) | Position statement | United States | NA | NA | NA | NA | NA | NA |
Endocrine Society, 2009 (32) | Guideline | United States | 72 | 33 | 63 | 58 | 8 | 46 |
Vancouver Coastal Health, Transcend Transgender Support & Education Society and Canadian Rainbow Health Coalition, 2006 (4) | Guideline | Canada | 86 | 61 | 17 | 89 | 0 | 0 |
Note: NA = not assessed.
↵* We did not assess the quality of position statements as they are unlikely to undergo the same development process as guidelines.